91 related articles for article (PubMed ID: 8655273)
21. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
22. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study.
Immonen A; Vapalahti M; Tyynelä K; Hurskainen H; Sandmair A; Vanninen R; Langford G; Murray N; Ylä-Herttuala S
Mol Ther; 2004 Nov; 10(5):967-72. PubMed ID: 15509514
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
Maleniak TC; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2001 Aug; 8(8):589-98. PubMed ID: 11571537
[TBL] [Abstract][Full Text] [Related]
25. Novartis reclaims tk technology.
Johnson E
Nat Biotechnol; 1997 Mar; 15(3):211. PubMed ID: 9062913
[No Abstract] [Full Text] [Related]
26. Transduction of thymidine phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor.
Manome Y; Watanabe M; Abe T; Tomita M; Watanabe S; Yokokawa Y; Takahashi Y; Ishii K; Kimura A; Murakami M; Nagata M; Shibata T; Nakamura M; Tanigawa N; Ohno T
Anticancer Res; 2001; 21(4A):2265-72. PubMed ID: 11724281
[TBL] [Abstract][Full Text] [Related]
27. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.
Wildner O; Morris JC; Vahanian NN; Ford H; Ramsey WJ; Blaese RM
Gene Ther; 1999 Jan; 6(1):57-62. PubMed ID: 10341876
[TBL] [Abstract][Full Text] [Related]
29. Suicide genes and bystander killing: local and distant effects.
Dilber MS; Smith CI
Gene Ther; 1997 Apr; 4(4):273-4. PubMed ID: 9176510
[No Abstract] [Full Text] [Related]
30. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
[TBL] [Abstract][Full Text] [Related]
31. [The biosafety of the HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme].
Adachi N; Könü DL; Frei K; Yonekawa Y
No Shinkei Geka; 2000 Nov; 28(11):965-74. PubMed ID: 11127592
[TBL] [Abstract][Full Text] [Related]
32. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
33. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models.
Mizuno M; Ryuke Y; Yoshida J
Cancer Gene Ther; 2002 Oct; 9(10):825-9. PubMed ID: 12224023
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.
Greco O; Powell TM; Marples B; Joiner MC; Scott SD
Cancer Gene Ther; 2005 Jul; 12(7):655-62. PubMed ID: 15818381
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
[TBL] [Abstract][Full Text] [Related]
36. Gene therapeutics: the future of brain tumor therapy?
Cutter JL; Kurozumi K; Chiocca EA; Kaur B
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1053-64. PubMed ID: 16831077
[TBL] [Abstract][Full Text] [Related]
37. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma.
Miletic H; Fischer YH; Giroglou T; Rueger MA; Winkeler A; Li H; Himmelreich U; Stenzel W; Jacobs AH; von Laer D
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6761-8. PubMed ID: 18006778
[TBL] [Abstract][Full Text] [Related]
38. [Gene therapy vector: adenovirus vector].
Saito I
Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1798-805. PubMed ID: 9279115
[No Abstract] [Full Text] [Related]
39. Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene.
Tamura K; Tamura M; Ikenaka K; Yoshimatsu T; Miyao Y; Nanmoku K; Shimizu K
Gene Ther; 2001 Feb; 8(3):215-22. PubMed ID: 11313793
[TBL] [Abstract][Full Text] [Related]
40. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results.
Colombo F; Barzon L; Franchin E; Pacenti M; Pinna V; Danieli D; Zanusso M; Palù G
Cancer Gene Ther; 2005 Oct; 12(10):835-48. PubMed ID: 15891772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
